Charles Schwab
RUBY

Charles Schwab’s Rubius Therapeutics, Inc RUBY Stock Holding History

Charles Schwab’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-217,621
Closed -$186K – 3569
2022
Q2 		$186K Sell
217,621
-74,256
-25% -$125K ﹤0.01% 3245
2022
Q1 		$1.61M Sell
291,877
-13,389
-4% -$85K ﹤0.01% 2719
2021
Q4 		$2.96M Buy
305,266
+6,144
+2% +$85.2K ﹤0.01% 2573
2021
Q3 		$5.35M Sell
299,122
-6,925
-2% -$151K ﹤0.01% 2342
2021
Q2 		$7.47M Buy
306,047
+33,256
+12% +$832K ﹤0.01% 2154
2021
Q1 		$7.23M Buy
272,791
+29,866
+12% +$436K ﹤0.01% 2121
2020
Q4 		$1.84M Buy
242,925
+7,303
+3% +$43.4K ﹤0.01% 2609
2020
Q3 		$1.18M Buy
235,622
+4,967
+2% +$26.3K ﹤0.01% 2637
2020
Q2 		$1.38M Buy
230,655
+17,219
+8% +$102K ﹤0.01% 2545
2020
Q1 		$950K Buy
213,436
+2,943
+1% +$21.9K ﹤0.01% 2504
2019
Q4 		$2M Buy
210,493
+3,499
+2% +$33.8K ﹤0.01% 2416
2019
Q3 		$1.63M Buy
206,994
+90,773
+78% +$1.06M ﹤0.01% 2453
2019
Q2 		$1.83M Buy
116,221
+11,506
+11% +$186K ﹤0.01% 2399
2019
Q1 		$1.9M Buy
104,715
+42,802
+69% +$657K ﹤0.01% 2379
2018
Q4 		$996K Sell
61,913
-740
-1% -$13.5K ﹤0.01% 2539
2018
Q3 		$1.5M Buy
+62,653
New +$1.43M ﹤0.01% 2512

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Charles Schwab's RUBY Position: Q3 2022 in Review

Charles Schwab sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 217,621 shares — an estimated $186K sold.

Charles Schwab first reported a position in RUBY in Q3 2018 and held it in 16 quarters. The position peaked at $7.47M in Q2 2021. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • Charles Schwab reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • Charles Schwab sold 217,621 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $186K.
  • Charles Schwab first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 16 quarters.
  • Charles Schwab's Rubius Therapeutics, Inc position peaked at $7.47M in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on Charles Schwab's 13F filing for Q3 2022, filed 14 Nov 2022.